StreetInsider.com News Articles

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

LUND, Sweden, May 27, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ STOCKHOLM: HNSA), today announced positive topline results from the European 20-HMedIdeS-19 Post Authorization Efficacy Study (PAES), an open-label confirmatory study investigating one-year graft failure-free survival^[*] and patient survival in highly sensitized patients who

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Wed, 27 May 2026 02:25:00 -0400

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Submission to EMA for conversion to full marketing authorization planned for Q4 2026

Hansa Biopharma trial results to be presented at transplant congress

Mon, 25 May 2026 22:52:43 -0400

Hansa Biopharma AB (NASDAQ Stockholm: HNSA) announced that results from its Phase 3 ConfIdeS trial in kidney transplantation have been selected for presentation at the American Transplant Congress in Boston on June 22, 2026.

The presentation will include 12-month results from the trial, focusing on the primary endpoint eGFR and key secondary endpoints, along with safety data. Dr. Robert Montgomery from New York University Langone Transplant Institute will deliver the presentation on behalf of the ConfIdeS study group.

The abstract, titled "Superior 1-year eGFR Among Highly Sensitized Patients Desensitized with Imlifidase Compared with Control," will be presented during the Late-Breaking Abstracts: Clinical

Hansa Biopharma trial results to be presented at transplant congress

Mon, 25 May 2026 22:52:43 -0400

The abstract, titled "Superior 1-year eGFR Among Highly Sensitized Patients Desensitized with Imlifidase Compared with Control," will be presented during the Late-Breaking Abstracts: Clinical

Hansa Biopharma trial results to be presented at transplant congress

Mon, 25 May 2026 22:52:43 -0400

The abstract, titled "Superior 1-year eGFR Among Highly Sensitized Patients Desensitized with Imlifidase Compared with Control," will be presented during the Late-Breaking Abstracts: Clinical